Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 7/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 7/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 7/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 6/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | HPGD | P15428 | 1/20 | 0.90 |
| ▸ | TSHR | P16473 | 1/20 | 0.90 |
| ▸ | BLM | P54132 | 1/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.90 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zardaverine SCHEMBL15263214 | 0.95 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Zardaverine SCHEMBL29388700 | 0.95 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Zardaverine SCHEMBL13334 | 0.95 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL10761953 | 0.88 | PDE4B (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL8479743 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL10764347 | 0.83 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL21969548 | 0.83 | PDE3A (0.70) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL10757789 | 0.80 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL8633588 | 0.80 | PDE4D (0.66) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL8996757 | 0.80 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-4665074-A | CARDIOTONIC, BRONCHOSPASMOLYTIC | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | PDE4A 432/4885PDE4B 530/4885PDE4C 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.